与炎症性肠病药物相关的严重COVID-19结局风险:来自prep - ibd的令人放心的见解

Abstracts of distinction Pub Date : 2021-11-01 DOI:10.1136/gutjnl-2021-bsg.41

C. Lamb, S. Sebastian, A. Kent, Jonathan P. Segal, H. Gonzalez, M. Brookes, S. Mehta, S. Subramanian, N. Bhala, L. Hicks, T. Conley, K. Patel, G. Walker, N. Kennedy

{"title":"与炎症性肠病药物相关的严重COVID-19结局风险:来自prep - ibd的令人放心的见解","authors":"C. Lamb, S. Sebastian, A. Kent, Jonathan P. Segal, H. Gonzalez, M. Brookes, S. Mehta, S. Subramanian, N. Bhala, L. Hicks, T. Conley, K. Patel, G. Walker, N. Kennedy","doi":"10.1136/gutjnl-2021-bsg.41","DOIUrl":null,"url":null,"abstract":"ATU-3 Frigure 1ConclusionsOur data provide reassurance for the continued evidence-based use of corticosteroids, immunomodulators and biologic therapies in IBD during the ongoing COVID-19 pandemic, and is consistent with an as yet unexplained association between mesalazine use and severe COVID-19 outcomes.","PeriodicalId":112484,"journal":{"name":"Abstracts of distinction","volume":"377 2","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ATU-3 Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from PREPARE-IBD\",\"authors\":\"C. Lamb, S. Sebastian, A. Kent, Jonathan P. Segal, H. Gonzalez, M. Brookes, S. Mehta, S. Subramanian, N. Bhala, L. Hicks, T. Conley, K. Patel, G. Walker, N. Kennedy\",\"doi\":\"10.1136/gutjnl-2021-bsg.41\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ATU-3 Frigure 1ConclusionsOur data provide reassurance for the continued evidence-based use of corticosteroids, immunomodulators and biologic therapies in IBD during the ongoing COVID-19 pandemic, and is consistent with an as yet unexplained association between mesalazine use and severe COVID-19 outcomes.\",\"PeriodicalId\":112484,\"journal\":{\"name\":\"Abstracts of distinction\",\"volume\":\"377 2\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Abstracts of distinction\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/gutjnl-2021-bsg.41\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Abstracts of distinction","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/gutjnl-2021-bsg.41","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

结论在2019冠状病毒病大流行期间，这些数据为持续使用皮质类固醇、免疫调节剂和生物疗法治疗IBD提供了保证，并且与使用美沙拉嗪与严重的COVID-19结局之间尚未解释的关联是一致的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

ATU-3 Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from PREPARE-IBD

ATU-3 Frigure 1ConclusionsOur data provide reassurance for the continued evidence-based use of corticosteroids, immunomodulators and biologic therapies in IBD during the ongoing COVID-19 pandemic, and is consistent with an as yet unexplained association between mesalazine use and severe COVID-19 outcomes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Abstracts of distinction

自引率

0.00%

发文量